1-2 of 2
Gregory Reid
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

Clinical Trials & Observations
Guillermo Garcia-Manero, Sarit Assouline, Jorge Cortes, Zeev Estrov, Hagop Kantarjian, Hui Yang, Willie M. Newsome, Wilson H. Miller, Jr, Caroline Rousseau, Ann Kalita, Claire Bonfils, Marja Dubay, Tracy-Ann Patterson, Zuomei Li, Jeffrey M. Besterman, Gregory Reid, Eric Laille, Robert E. Martell, Mark Minden
Journal: Blood
Blood (2008) 112 (4): 981–989.
https://doi.org/10.1182/blood-2007-10-115873
Published: 2008
Includes: Supplemental data
Journal Articles

A Phase I Study of the Histone Deacetylase Inhibitor MGCD0103 (MG-0103) Given as a Three-Times Weekly Oral Dose in Patients with Leukemia or Myelodysplastic Syndromes (MDS).

Guillermo Garcia-Manero, MD, Mark Minden, MD, Zeev Estrov, MD, Srdan Verstovsek, MD, Jackie Fiorentino, RN, Hagop Kantarjian, MD, Gregory Reid, Robert E. Martell, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 4639.
https://doi.org/10.1182/blood.V106.11.4639.4639
Published: 2005